Protalix BioTherapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CARMIEL, Israel, Sept. 6, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the Company will present at the H.C. Wainwright 24th Annual Global Investment Conference, a hybrid conference. The conference is being held on September 12-14, 2022 at the Lotte New York Palace Hotel in New York City. Virtual participation will also be available.
Dror Bashan, the Company's President and Chief Executive Officer, will provide a corporate overview at the conference. A webcast of the presentation will be available commencing on Monday, September 12, 2022 at 7:00 AM, Eastern time, and will be archived.
The conference will be webcast live from the Company's website and will be available via the following links:
Company Link: https://protalixbiotherapeutics.gcs-web.com/events0
Webcast Link: https://journey.ct.events/view/326342b0-083d-4eca-81f7-f93cc78d3394
The Company's management will participate in one-on-one meetings with investors who are registered to attend the conference. If you are an institutional investor and would like to attend the Company's presentation, registration for the conference is available at https://hcwevents.com. Once your registration is confirmed, you will be prompted to log onto the conference website to request a one-on-one meeting with the Company.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; alidornase alfa or PRX–110, for the treatment of various human respiratory diseases or conditions; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Chuck Padala, Managing Director
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301618133.html
SOURCE Protalix BioTherapeutics, Inc.
Company Codes: AMEX:PLX, Frankfurt:PBDA, Dusseldorf:PBD, Berlin:PBDA, Dusseldorf:PBDA, Munich:PBDA, TelAviv:PLX, Stuttgart:PBD